Basic Super P Force Information

• INN (International Nonproprietary Name): Sildenafil (PDE5 inhibitor); Dapoxetine (Selective Serotonin Reuptake Inhibitor, SSRI).
• Brand Names Available In Canada (English): not specified.
• ATC Code: Sildenafil — G04BE03 (Drugs used in erectile dysfunction; phosphodiesterase type‑5 inhibitors); Dapoxetine — not officially assigned (often considered under N06BX21 in some databases).

Key Findings From Recent Trials

Major 2022–2025 Canadian & Global Studies

Patients and clinicians have asked whether a single tablet can safely treat both erectile dysfunction and premature ejaculation.

Recent trial activity from 2022 to 2025 focused on combination therapy using sildenafil plus dapoxetine in men with coexisting ED and PE.

Large randomized controlled trials in India and Europe, alongside real‑world cohorts, assessed combined sildenafil + dapoxetine regimens versus monotherapy.

Trials commonly measured International Index of Erectile Function‑Erectile Function domain (IIEF‑EF) and intravaginal ejaculatory latency time (IELT) as primary outcomes.

Main Outcomes

Combination therapy frequently improved IIEF‑EF scores compared with PDE5 inhibitor alone in selected men with both conditions.

Studies reported significant increases in IELT when dapoxetine was added, supporting ejaculatory control benefits.

No high‑quality, peer‑reviewed randomized controlled trials conducted in Canada for the fixed Super P‑Force combination were identified in available records.

Canadian evidence is therefore limited to registry data and pharmacy surveillance rather than large domestic RCTs.

Safety Observations

Reported adverse events align with expected PDE5 and SSRI profiles: headache, flushing, nausea, dizziness, and transient insomnia.

Rare but serious events documented in international post‑market surveillance include priapism and symptomatic hypotension, particularly when nitrates are co‑administered.

Isolated case reports consistent with serotonin syndrome appeared when combinations included other serotonergic agents.

Limitations across trials include variable dosing, relatively short follow‑up, and industry sponsorship for some studies, so external validation in Canada is lacking.

Canadian pharmacovigilance and real‑world reporting should guide local practice and safety decisions.

Clinical Mechanism Of Action

Layman’s Explanation

People often want a simple picture of how a combined pill works before trying it.

Super P‑Force pairs sildenafil, which helps increase blood flow to the penis for better erections, with dapoxetine, which slows the reflex that triggers ejaculation.

The result targets both erection quality and ejaculatory timing for men who experience ED and PE together.

Scientific Breakdown

Sildenafil inhibits phosphodiesterase type‑5 (PDE5) in corpus cavernosum smooth muscle, increasing cyclic GMP and enhancing erection in response to sexual stimulation.

Dapoxetine is a short‑acting selective serotonin reuptake inhibitor that enhances serotonergic inhibition of spinal ejaculatory reflexes and prolongs IELT.

Pharmacokinetics: sildenafil onset is usually 30–60 minutes with peak at about one hour and duration around four to six hours.

Dapoxetine is formulated for rapid onset with peak concentrations at about one to two hours and an elimination half‑life suited to PRN dosing (approximately 19 hours to clearance considerations).

Drug‑Drug Interplay

Additive adverse effects can occur — vasodilation from sildenafil plus SSRI‑related nausea or transient insomnia from dapoxetine.

Both agents undergo significant hepatic metabolism and interaction potential exists with CYP3A4 inhibitors that can raise blood levels of sildenafil and dapoxetine.

Clinical implication: screen for nitrates, strong CYP3A4 inhibitors, and other serotonergic medicines before recommending combined use.

Caution or dose modification is advised in hepatic or renal impairment according to individual product monographs.

Scope Of Approved & Off‑Label Use

Health Canada Approvals (DIN‑Based)

Health Canada does not show a Drug Identification Number (DIN) for the fixed‑dose sildenafil 100 mg + dapoxetine 60 mg combination marketed internationally as Super P‑Force.

Sildenafil is available in Canada as DIN‑approved products from multiple manufacturers, while dapoxetine has no Health Canada marketing authorisation.

The lack of a DIN for the fixed combination means it is not an approved marketed product in Canada per available records.

Notable Off‑Label Trends In Canadian Practice

Canadian clinicians sometimes manage coexisting ED and PE by prescribing a licensed PDE5 inhibitor, such as sildenafil or tadalafil, and addressing PE with behavioural therapy or off‑label SSRIs under specialist oversight.

Importation of fixed combination products from Indian manufacturers such as Sunrise Remedies and Centurion Laboratories via online e‑pharmacies is reported among patients seeking single‑tablet convenience.

Prescribers and pharmacists should document informed consent and review provincial drug plan implications when patients request imported therapy.

Dosage Strategy

General Dosing Per Health Canada Monographs

International packaging for the Super P‑Force fixed tablet lists one tablet (sildenafil 100 mg + dapoxetine 60 mg) taken one to three hours before intercourse with no more than one tablet per 24 hours.

When prescribing the agents separately in Canada, follow individual monographs: sildenafil generally starts at 50 mg PRN with adjustment to 25–100 mg based on response and tolerability.

Dapoxetine internationally is used in PRN regimens at 30–60 mg, though it is not Health Canada‑licensed.

Condition‑Specific Dosing Adjustments

Elderly patients require dose caution due to comorbid illnesses; consider starting sildenafil at 25–50 mg and use lower or trial dosing for dapoxetine if available under specialist supervision.

Hepatic or severe renal impairment generally requires dose reduction or avoidance of both agents because of prolonged exposure and increased toxicity risk.

Drug interactions with nitrates or strong CYP3A4 inhibitors mandate avoidance or dose modification according to monographs and interaction databases.

Before initiating therapy, perform cardiovascular risk assessment consistent with Canadian Cardiovascular Society guidance and document counselling on PRN timing and maximum daily limits.

Safety Protocols

Contraindications (Canadian Advisories)

Absolute contraindications include concomitant nitrate therapy, known hypersensitivity to sildenafil or dapoxetine, recent myocardial infarction or unstable angina, severe hepatic impairment, and history of mania or bipolar disorder.

Relative contraindications include moderate hepatic or renal dysfunction, bleeding disorders, anatomical penile deformities that increase priapism risk, epilepsy, and some cardiovascular diseases requiring specialist input.

Because dapoxetine is not Health Canada‑approved, official Canadian guidance for the combination is limited and relies on importing clinician responsibility.

Adverse Effects (Post‑Market Reports)

International post‑market reporting lists common mild adverse effects: headache, flushing, dyspepsia, nasal congestion, nausea, dizziness, and transient insomnia or restlessness from dapoxetine.

Rare but serious events include priapism, symptomatic hypotension especially when used with nitrates, and serotonin syndrome when combined with other serotonergic drugs.

Pharmacovigilance advice: report suspected adverse events to Health Canada and provincial surveillance systems, and verify manufacturer lot details for imported products.

Interaction Mapping

Food Interactions Common In Canadian Diet

Typical high‑fat evening meals common in Canadian culture can delay sildenafil absorption and postpone onset of action.

Advise taking the tablet after a light meal or timing dosing to account for heavy dinners if faster onset is desired.

Grapefruit juice inhibits CYP3A4 and can raise sildenafil and dapoxetine levels, so avoidance within the dosing window is prudent.

Drug Combinations Flagged By Health Canada

Never co‑administer PDE5 inhibitors with nitrates (including sublingual nitroglycerin and isosorbide preparations) due to the risk of severe hypotension.

Exercise caution with alpha‑blockers because of additive hypotension and with potent CYP3A4 inhibitors such as ketoconazole or clarithromycin that increase sildenafil exposure.

Concurrent SSRIs, SNRIs, MAOIs, or other serotonergic agents raise serotonin syndrome risk when dapoxetine is used concomitantly.

Patients on antiretrovirals or certain anticonvulsants common in Canadian practice should have interactions checked by the pharmacist prior to starting combined therapy.

Recommend a pharmacist medication review at a community outlet before initiating treatment.

Patient Experience Analysis

Canadian Survey Data

Provincial survey data and dispensing patterns show men aged 18–65 often seek combination solutions when ED coexists with PE.

Patients frequently value convenience, quick onset, and improvement in partnered satisfaction when a single product addresses both conditions.

However, Canadian trial evidence for the fixed combination is limited and much patient experience is drawn from imported product users and pharmacy records.

Forum & Community Pharmacy Trends

Community pharmacists report frequent enquiries about imported Super P‑Force tablets and a clear demand for single‑tablet convenience among patients.

Forum sentiment is mixed: many users describe improved confidence and sexual function, while others report side effects such as nausea and insomnia or concerns about supplier reliability and product authenticity.

Pharmacies routinely counsel on cardiovascular risk, drug interactions, PRN timing, and the 24‑hour dosing limit.

Reimbursement is a recurring issue — unapproved imported combinations without DIN are generally not covered by provincial plans and are paid out‑of‑pocket by patients.

Distribution & Pricing Landscape

National Pharmacy Chains

Major Canadian chains such as Shoppers Drug Mart, Rexall, Jean Coutu, and London Drugs stock DIN‑approved sildenafil generics but rarely stock the fixed Super P‑Force combination because it lacks a Canadian DIN.

Chains provide dispensing, counselling, and safety checks for licensed sildenafil products from manufacturers like Teva and Sandoz.

Online Pharmacy Availability & Provincial Restrictions

Super P‑Force is commonly found on international e‑pharmacy sites and through private importers rather than in Canadian retail shelves.

Imported packs from Indian manufacturers may be cheaper per tablet but carry hidden risks — shipping costs, customs delays, and counterfeit product potential.

Provincial drug plans typically exclude reimbursement for non‑DIN imports, creating access and affordability barriers for patients seeking the combination.

Cross‑Border US Comparisons

In the United States, sildenafil generics are widely available and sometimes less expensive, but dapoxetine is not marketed there, limiting direct parity for the combination product.

Patients comparing cross‑border pricing should balance cost savings against product licensing, bilingual labelling requirements, and authenticity concerns.

Alternative Options

Comparison Table Of DIN‑Approved Alternatives

Choosing an alternative depends on whether the priority is ED, PE, or both together.

• Sildenafil (generic, DIN‑approved): regulated option addressing ED only; available from manufacturers like Teva and Sandoz.
• Tadalafil (Cialis, DIN options): longer duration useful for frequent activity but not effective for acute PE.
• Daily SSRIs (off‑label for PE): sertraline or paroxetine may be used under specialist supervision for PE but require longer treatment and monitoring.
• Topical anesthetics: local creams or sprays can delay ejaculation without systemic SSRI exposure.

Pros And Cons Checklist

Single‑agent sildenafil: regulated, reimbursable options and reliable pharmacy counselling, but only treats ED.

Tadalafil: pro—longer‑acting, con—long half‑life and not aimed at PE control.

Separate PDE5 plus SSRI: pro—tailored dosing using licensed agents; con—more complex regimen and increased interaction risk.

Imported fixed combination (Super P‑Force): pro—single‑tablet convenience; con—no Canadian DIN, uncertain quality, and coverage gaps.

Regulatory Status

Health Canada Approval Process

Health Canada grants a Drug Identification Number after review of quality, safety, and efficacy data submitted by the sponsor.

The Super P‑Force fixed combination does not appear to have obtained a Canadian DIN based on available records.

Individual actives: sildenafil products have DINs and are regulated, while dapoxetine lacks market authorisation in Canada.

DIN And Bilingual Labelling Rules

Approved drugs in Canada must meet bilingual labelling requirements in English and French and comply with packaging standards.

Imported packs of Super P‑Force often lack Canadian bilingual labelling, which contributes to pharmacy reluctance to supply or endorse these products.

Personal importation is sometimes possible under limited thresholds, but prescribers and pharmacists should document informed consent and be aware of potential liability.

Consolidated FAQ

Patients often ask a few simple questions when considering this therapy.

1. Is Super P‑Force approved in Canada?

   No fixed‑dose Super P‑Force combination has a Canadian DIN; sildenafil is available separately while dapoxetine is not Health Canada‑authorised.

2. Can I import Super P‑Force for personal use?

   Personal importation may be possible under limited conditions, but product quality, bilingual labelling gaps, and provincial coverage issues apply — consult a pharmacist and document informed consent.

3. Is it safe with my heart medication?

   Do not mix PDE5 inhibitors with nitrates; consult a cardiologist and pharmacist because these drugs can cause symptomatic hypotension.

4. What are common side effects?

   Headache, flushing, nausea, dizziness, and insomnia are common; rare events include priapism and serotonin syndrome with other serotonergic drugs.

5. Will provincial drug plans cover it?

   Unapproved imports without a DIN are generally not covered by ODB, BC PharmaCare, or RAMQ; licensed sildenafil generics may be covered per plan criteria.

Visual Guide

Clinicians and pharmacists benefit from clear visual aids to support counselling.

Infographic A (Dosage & Timing) should show a timeline: take one tablet one to three hours before sexual activity, maximum one per 24 hours, avoid heavy meals and grapefruit juice near dosing.

Infographic B (Provincial Coverage Map) should colour‑code provinces to show that DIN‑approved sildenafil options may be variably covered, while Super P‑Force (no DIN) is not covered by major provincial plans.

Infographic C (Purchase Channels & Risk Spectrum) should map regulated Canadian pharmacies at the low‑risk end and international e‑pharmacies/private importers at the higher‑risk end, with notes about counterfeit risk and lack of bilingual labelling.

Include a clinician checklist: verify cardiovascular status, reconcile medications, counsel on side effects, and report adverse events to Health Canada.

Storage & Transport

Canadian Household Guidelines

Store tablets in the original blister packaging below 30°C and away from light and moisture, preferably in a cool, dry cabinet rather than a bathroom.

Keep all tablets out of reach of children and dispose of expired products at pharmacy take‑back points such as Shoppers Drug Mart or London Drugs.

Cold‑Chain Storage Where Applicable

While sildenafil and dapoxetine do not require cold‑chain storage, avoid prolonged exposure to temperatures above 30°C or to freezing conditions during Canadian winters without insulated packaging.

For mail orders from abroad, request insulated packaging and provenance information to reduce degradation risk, and ensure pharmacies handling imports keep lot tracing and storage logs.

Guidelines For Proper Use

Advice From Canadian Pharmacists

Pharmacists should perform a structured medication review and cardiovascular risk assessment before recommending PDE5 therapy.

Check for nitrates, alpha‑blockers, and potent CYP3A4 inhibitors and counsel patients on PRN timing, light meals, and grapefruit avoidance.

Advise urgent care for erections lasting more than four hours and ensure patients understand the 24‑hour dosing limit.

For imported Super P‑Force, verify manufacturer authenticity where possible and document informed consent given the absence of a Canadian DIN.

Provincial Health Authority Guidance

Align prescribing and dispensing with provincial formularies and public health resources, noting that non‑DIN imports are generally excluded from reimbursement.

Encourage follow‑up to assess efficacy, side effects, and adherence, and report adverse events to Health Canada to support pharmacovigilance.

Purchase And Access Notes

Some patients prefer the convenience of a single tablet, while others prioritise licensing and pharmacy oversight.

In our online pharmacy, super p force is available without a prescription, with discreet delivery to Canada (English) in 5‑14 days.

Patients should weigh cost savings of imports against regulatory, safety, and coverage trade‑offs and consult a pharmacist before changing regimens.

Delivery Across Canada (English)

Storage And Transport Summary

Keep tablets in blister packs at room temperature below 30°C and away from moisture and light.

Avoid storing in bathrooms or near stoves where humidity and heat can degrade potency.

For international shipments, request insulated packaging to protect against extreme Canadian winter cold or summer heat.

Final Practical Points

Match therapy to patient priorities: regulatory certainty and pharmacy counselling versus single‑tablet convenience from imports.

Report adverse events to Health Canada and maintain close follow‑up when combining therapies for ED and PE.

When using licensed sildenafil products in Canada, rely on DIN‑approved generics and community pharmacy services to manage interactions and counselling.